首页 国际期刊 医学期刊 期刊详情(非官网)
400-808-1701

Cancer

Cancer杂志,由John Wiley and Sons Inc.出版,于1947年创刊,Semimonthly,出版语言English,ISSN:0008-543X,E-ISSN:1097-0142。

投稿咨询
Cancer
Cancer
Cancer
SCI SCIE

杂志介绍

JCR分区
Q1
中科院分区
2区
影响因子
5.6
CiteScore
10.6
期刊收录
SCI、SCIE

Cancer(中文译名:《癌症》),ISSN:0008-543X,EISSN:1097-0142,是John Wiley and Sons Inc.出版的国际性学术期刊,创刊于1947年,以Semimonthly形式稳定发行,2026年总发文量约327篇。该刊采用非OA开放访问,学科归属为医学 - 肿瘤学。该刊是医学、肿瘤学领域的国际权威刊物,已被SCI(科学引文索引)、SCIE(科学引文索引扩展版)等国际主流学术数据库收录。2026年期刊影响因子达5.6,2025年期刊CiteScore为10.6,2025年期刊自引率约1.8%,在中科院期刊分区体系中位列医学大类2区TOP 期刊,在所属学科领域具备高学术影响力与国际认可度。Cancer长期聚焦医学、肿瘤学及相关产业的技术应用前沿,平均审稿周期很快,2-3周,审稿流程高效稳定。在稿件录用评判中,该刊将创新性与前沿性作为核心遴选标准,重点收录能够对医学、肿瘤学领域的落地与发展产生实质性推动价值的研究成果。

从全球发文格局来看,USACanada、CHINA MAINLAND、England、GERMANY (FED REP GER)、Italy、France等为核心发文国家与地区;HARVARD UNIVERSITYUNIVERSITY OF TEXAS SYSTEM、UNIVERSITY OF CALIFORNIA SYSTEM、DANA-FARBER CANCER INSTITUTE、MEMORIAL SLOAN KETTERING CANCER CENTER、EMORY UNIVERSITY、BRIGHAM & WOMEN'S HOSPITAL等高校与科研机构是期刊的主要发文单位。

期刊评价

名词解释:

影响因子(Impact Factor, IF):指该期刊前两年发表的文章,在第三年的平均被引用次数。它反映了期刊的近期平均影响力和热度。

中科院分区:中科院分区表是国内主流的学术期刊分级评价工具,核心意义是建立跨学科可比的统一评价标尺,为职称评审、学位授予、科研立项等科研管理工作提供标准化量化依据,同时帮助科研人员筛选优质期刊、规避学术风险,适配国内本土化的科研评价需求。

期刊分区表

《新锐期刊分区表》(2026年3月发布)

大类学科 小类学科 Top期刊 综述期刊
医学
2区
ONCOLOGY 肿瘤学
2区

期刊分区表(2025年3月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
1区
ONCOLOGY 肿瘤学
2区

期刊分区表(2023年12月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
2区
ONCOLOGY 肿瘤学
2区

JCR分区

2025-2026年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:ONCOLOGY SCIE Q1 74 / 333

77.9

学科:ONCOLOGY SCIE Q1 69 / 333

79.43

2024-2025年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:ONCOLOGY SCIE Q1 68 / 328

79.4

学科:ONCOLOGY SCIE Q1 58 / 328

82.47


中国学者近期发文

1
Reply to Comments on chemoradiotherapy in IDH wild-type/TERT-mutant grade 2/3 glioma

Author:Zhang, Jing; Wang, Peng; Ren, Yin; Chen, Li; Feng, Jin; Liu, Fei; Deng, Kaiwen; Bao, Zhaoshi; Qiu, Xiaoguang; Liu, Yanwei

Journal: CANCER. 2026; Vol. 132, Issue 8, pp. -. DOI: 10.1002/cncr.70359

2
Diagnostic performance analysis of two-gene methylation in urothelial carcinoma based on small-volume urine sampl

Author:Wu, Zhiming; Cao, Lin; Zeng, Jiamin; Feng, Weici; Zhou, Qianghua; Deng, Xinpei; Zhang, Liang; Tan, Xingliang; Wang, Yanjun; Cao, Jiazheng; Xie, Yu; Xu, Abai; Yao, Kai

Journal: CANCER. 2026; Vol. 132, Issue 7, pp. -. DOI: 10.1002/cncr.70373

3
Final clinical data of a phase 1 dose-escalation study of WVT078, a BCMA×CD3 bispecific antibody, alone and in combination with γ-secretase inhibitor WHG626 in patients with relapsed and/or refractory multiple myelom

Author:Schjesvold, Fredrik; Spencer, Andrew; Cohen, Yael C.; Ocio, Enrique M.; Lopez‐Pardo, Jordi; Cafro, Anna Maria; Callander, Natalie S.; Kaufman, Jonathan L.; Mohan, Meera; Wermke, Martin; Doki, Noriko; Kan, Rebecca; Milanez‐Almeida, Pedro; Stein, Andrew; Trabucco, Gina; Ye, Stan; Kulec, Karolina; Sechaud, Romain; Banerjee, Souvik; Zhong, Huiqin; Lai, Clinton; Rauch, Philipp J.; Raab, Marc S

Journal: CANCER. 2026; Vol. 132, Issue 7, pp. -. DOI: 10.1002/cncr.70341

4
Poor clinical outcomes and immunoevasive contexture in gastric cancer patients bearing p16 high phenotyp

Author:Wang, Jieti; Gu, Yun; Zhang, Ziqiu; Ling, Zhen; Lin, Chao; Liu, Hao; Li, Ruochen; He, Hongyong; Shao, Fei; Xu, Jiejie

Journal: CANCER. 2026; Vol. 132, Issue 6, pp. -. DOI: 10.1002/cncr.70363

5
Durvalumab combined with concurrent chemoradiotherapy in patients with limited-stage small cell lung cancer: A prospective, single-arm, phase 2 clinical tria

Author:Song, Chunyang; Zhao, Xiaohan; Li, Shuguang; Guo, Xuehan; Zhang, Xueyuan; Wang, Xiaobin; Li, Youmei; Yan, Ke; Su, Jingwei; Xu, Jinrui; Zhu, Shuchai; Shen, Wenbin

Journal: CANCER. 2026; Vol. 132, Issue 6, pp. -. DOI: 10.1002/cncr.70351

6
Long-term outcomes of newly diagnosed POEMS syndrome patients treated with bortezomib-based therapie

Author:He, Haiyan; Fu, Qingcheng; Yu, Xuerou; Chen, Xi; Lu, Jing; Jin, Lina; Fan, Xiaoqiang; Du, Juan

Journal: CANCER. 2026; Vol. 132, Issue 4, pp. -. DOI: 10.1002/cncr.70293

7
T-cell receptor-like chimeric antigen receptor T cells targeting mesothelin: A first-in-human dose-escalation trial for platinum-resistant advanced ovarian cance

Author:Shan, Yiyang; Ding, Bo; Ji, Feng; Lin, Hao; Shi, Weiwei; Wang, Enxiu; Wang, Chen; Shen, Yang

Journal: CANCER. 2026; Vol. 132, Issue 3, pp. -. DOI: 10.1002/cncr.70279

8
The evolution and prognostic impact of HER2-low, HER2-ultralow, and HER2-null status in HER2-negative early breast cancer: A pre- to post-neoadjuvant chemotherapy stud

Author:Qiu, Yibin; Wu, Long; Cai, Weifeng; Chen, Minyan; Jiang, Meichen; Wang, Yali; Liu, Shunyi; He, Peng; Lin, Yuxiang; Chen, Lili; Yang, Yinghong; Wang, Chuan; Zhang, Jie; Fu, Fangmeng

Journal: CANCER. 2026; Vol. 132, Issue 3, pp. -. DOI: 10.1002/cncr.70269

9
The safety of trastuzumab deruxtecan (T-DXd) in breast cancer brain metastases with a focus on interstitial lung disease/pneumonitis: A systematic review and meta-analysi

Author:Ma, Yiwen; Li, Xiaorui; Jiang, Yujun; Xiao, Liping; Sun, Tao

Journal: CANCER. 2026; Vol. 132, Issue 3, pp. -. DOI: 10.1002/cncr.70268

10
Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma: A cost-effectiveness analysi

Author:Luo, Jiefeng; Li, Zhengxiong; Ge, Jun; Cai, Sizhen; Mo, Xinyi; Liu, Wensheng; Gui, Chengxia; Du, Qiong; Liu, Jiyong

Journal: CANCER. 2026; Vol. 132, Issue 3, pp. -. DOI: 10.1002/cncr.70259


在线咨询

Cancer

国际简称:CANCER-AM CANCER SOC参考译名:癌症

年发文量:327 CiteScore:10.6 是否预警:否 Gold OA文章占比:40.30% 研究类文章占比:88.69%

杂志社联系方式:JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, USA, NJ, 07030

Cancer